Avita Medical Inc. (RCEL)
RCEL Stock Price Chart
Explore Avita Medical Inc. interactive price chart. Choose custom timeframes to analyze RCEL price movements and trends.
RCEL Company Profile
Discover essential business fundamentals and corporate details for Avita Medical Inc. (RCEL) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
14 May 2012
Employees
232.00
Website
https://avitamedical.comCEO
Cary G. Vance
Description
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.
RCEL Financial Timeline
Browse a chronological timeline of Avita Medical Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.29, while revenue estimate is $20.25m.
Earnings released on 14 May 2026
EPS came in at -$0.35 matching the estimated -$0.35, while revenue for the quarter reached $19.25m , beating expectations by +5.22%.
Earnings released on 12 Feb 2026
EPS came in at -$0.38 falling short of the estimated -$0.36 by -4.27%, while revenue for the quarter reached $17.43m , missing expectations by -2.27%.
Earnings released on 6 Nov 2025
EPS came in at -$0.46 falling short of the estimated -$0.43 by -6.98%, while revenue for the quarter reached $17.06m , missing expectations by -36.48%.
Earnings released on 7 Aug 2025
EPS came in at -$0.38 falling short of the estimated -$0.26 by -46.15%, while revenue for the quarter reached $12.03m , missing expectations by -70.09%.
Earnings released on 8 May 2025
EPS came in at -$0.53 falling short of the estimated -$0.39 by -35.90%, while revenue for the quarter reached $11.63m , missing expectations by -68.87%.
Earnings released on 13 Feb 2025
EPS came in at -$0.44 falling short of the estimated -$0.30 by -46.67%, while revenue for the quarter reached $11.39m , missing expectations by -63.94%.
Earnings released on 7 Nov 2024
EPS came in at -$0.62 falling short of the estimated -$0.42 by -47.62%, while revenue for the quarter reached $13.52m , missing expectations by -61.77%.
Earnings released on 8 Aug 2024
EPS came in at -$0.60 falling short of the estimated -$0.59 by -1.69%, while revenue for the quarter reached $10.13m , missing expectations by -31.22%.
Earnings released on 13 May 2024
EPS came in at -$0.73 falling short of the estimated -$0.26 by -180.77%, while revenue for the quarter reached $7.21m , missing expectations by -34.79%.
Earnings released on 22 Feb 2024
EPS came in at -$0.28 surpassing the estimated -$0.34 by +17.65%, while revenue for the quarter reached $9.66m , missing expectations by -33.35%.
Earnings released on 9 Nov 2023
EPS came in at -$0.34 surpassing the estimated -$0.53 by +35.85%, while revenue for the quarter reached $13.58m , beating expectations by +1.60%.
Earnings released on 10 Aug 2023
EPS came in at -$0.41 falling short of the estimated -$0.34 by -20.59%, while revenue for the quarter reached $11.72m , beating expectations by +3.52%.
Earnings released on 11 May 2023
EPS came in at -$0.37 falling short of the estimated -$0.22 by -68.18%, while revenue for the quarter reached $7.08m , missing expectations by -37.42%.
Earnings released on 23 Feb 2023
EPS came in at -$0.21 surpassing the estimated -$0.32 by +34.38%, while revenue for the quarter reached $6.46m , missing expectations by -37.45%.
Earnings released on 10 Nov 2022
EPS came in at -$0.22 surpassing the estimated -$0.32 by +31.25%, while revenue for the quarter reached $9.21m , beating expectations by +23.10%.
Earnings released on 11 Aug 2022
EPS came in at -$0.25 surpassing the estimated -$0.35 by +28.57%, while revenue for the quarter reached $8.30m , beating expectations by +13.45%.
Earnings released on 12 May 2022
EPS came in at -$0.38 falling short of the estimated -$0.36 by -5.56%, while revenue for the quarter reached $7.54m , beating expectations by +4.13%.
Earnings released on 28 Feb 2022
EPS came in at -$0.34 surpassing the estimated -$0.43 by +20.93%, while revenue for the quarter reached $6.94m , missing expectations by -76.88%.
Earnings released on 8 Nov 2021
EPS came in at -$0.24 surpassing the estimated -$0.40 by +40.00%, while revenue for the quarter reached $7.02m , beating expectations by +0.29%.
Earnings released on 26 Aug 2021
EPS came in at -$0.19 surpassing the estimated -$0.32 by +40.63%, while revenue for the quarter reached $10.30m , beating expectations by +24.52%.
RCEL Stock Performance
Access detailed RCEL performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
